Record Nr. UNINA9910451478803321 International benchmarking of US immunology research [[electronic **Titolo** resource] /] / Panel on International Benchmarking of US Immunology Research, Committee on Science, Engineering, and Public Policy, National Academy of Sciences, National Academy of Engineering, Institute of Medicine Washington, DC,: National Academy Press, 1999 Pubbl/distr/stampa Descrizione fisica 1 online resource (60 p.) Disciplina 616.079072 Soggetti Immunology - Research **Immunity** Electronic books. Lingua di pubblicazione Inglese **Formato** Materiale a stampa Livello bibliografico Monografia Note generali "Prepublication copy." Nota di bibliografia Includes bibliographical references. Nota di contenuto ""INTERNATIONAL BENCHMARKING OF US IMMUNOLOGY RESEARCH"": ""Copyright""; ""PREFACE""; ""CONTENTS""; ""EXECUTIVE SUMMARY""; ""1 INTRODUCTION""; ""1.1 HOW IMPORTANT IS IT FOR THE UNITED STATES TO LEAD IN IMMUNOLOGY RESEARCH?""; ""1.2 WHAT IS IMMUNOLOGY?""; ""1.3 IMMUNOLOGY AS AN ACADEMIC DISCIPLINE""; ""1.4 WHAT IS THE INTERNATIONAL NATURE OF IMMUNOLOGY?""; ""1.5 WHAT ARE SOME CAVEATS?""; ""1.6 PANEL CHARGE AND RATIONALE""; ""2 BENCHMARKING RESULTS""; ""2.1 METHODS""; ""2.1.1 Reputation Survey""; ""2.1.2 Citation Analysis""; ""2.1.3 Journal Publication Analysis": ""2.2 RESULTS"" ""2.2.1 Reputation Survey"""2.2.2 Citation Analysis""; ""2.2.3 Journal Publication Analysis""; ""2.3 SUMMARY""; ""3 KEY FACTORS""; ""3.1 FUNDING""; ""3.2 HUMAN RESOURCES""; ""3.3 INFRASTRUCTURE""; ""3.4 BIOTECHNOLOGY AND PHARMACEUTICAL FIRMS""; ""3.5 THE CLINICAL TRIAL""; ""4 LIKELY FUTURE POSITION""; ""4.1 FUNDING AND RESOURCE LIMITATIONS""; ""4.2 INCREASED COMPETITION FROM EUROPE AND OTHER COUNTRIES""; ""4.3 CLINICAL IMMUNOLOGY AND THE SHIFT

AND CONCLUSIONS""

TOWARD HMOS""; ""4.4 TRAINING OF US STUDENTS""; ""5 SUMMARY

""5.1 THE UNITED STATES IS THE WORLD LEADER IN ALL THE MAJOR SUBFIELDS OF IMMUNOLOGY BUT IS ONLY AMONG THE WORLD LEADERS INa€?"""5.2 FLEXIBILITY TO PURSUE ORIGINAL AND INNOVATIVE RESEARCH IDEAS HAS ATTRACTED BOTH DOMESTIC AND INTERNATIONAL HUMANa€?""; ""5.3 INDUSTRIAL INTERESTS HAVE FOSTERED MANY STRIKING BREAKTHROUGHS IN IMMUNOLOGY""; ""5.4 A SCARCITY OF LARGE-SCALE CLINICAL TRIALS IN IMMUNOLOGY CAN BE ATTRIBUTED TO SHORTAGES OF FUNDING AND OF QUALIFIEDa€?""; ""5.5 SHIFTING FEDERAL AND INDUSTRY PRIORITIES, A POTENTIAL REDUCTION IN ACCESS TO DOMESTIC AND FOREIGN TALENT, AND THEA €?""

""REFERENCES"""APPENDIX PANEL AND STAFF BIOGRAPHICAL INFORMATION""; ""STAFF""